LSA
REGN icon

L & S Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

L & S Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,653
Closed -$3.59M – 260
2025
Q4 		$3.59M Buy
+4,653
New +$3.16M 0.33% 91
2020
Q4 		– Sell
-6,894
Closed -$3.86M – 358
2020
Q3 		$3.86M Sell
6,894
-204
-3% -$124K 0.53% 68
2020
Q2 		$4.43M Buy
+7,098
New +$4.03M 0.66% 45
2018
Q1 		– Sell
-1,872
Closed -$704K – 325
2017
Q4 		$704K Buy
1,872
+212
+13% +$85.9K 0.11% 153
2017
Q3 		$742K Sell
1,660
-160
-9% -$76.1K 0.12% 136
2017
Q2 		$894K Buy
1,820
+607
+50% +$266K 0.16% 131
2017
Q1 		$470K Buy
+1,213
New +$450K 0.09% 161

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

L & S Advisors's REGN Position: Q1 2026 in Review

L & S Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 4,653 shares — an estimated $3.59M sold.

L & S Advisors first reported a position in REGN in Q1 2017 and held it in 7 quarters. The position peaked at $4.43M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • L & S Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • L & S Advisors sold 4,653 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $3.59M.
  • L & S Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2017 and held it in 7 quarters.
  • L & S Advisors's Regeneron Pharmaceuticals position peaked at $4.43M in Q2 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on L & S Advisors's 13F filing for Q1 2026, filed 11 May 2026.